Clinical Trials Directory

Trials / Completed

CompletedNCT00343616

Cognitive Function in Postmenopausal Women With Breast Cancer Receiving Hormone Therapy on Clinical Trial IBCSG-1-98

Investigating Cognitive Function for Patients Participating in the BIG Trial 1-98 in Select Centers

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
135 (actual)
Sponsor
ETOP IBCSG Partners Foundation · Network
Sex
Female
Age
30 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying cognitive function, such as thinking, attention, concentration, and memory, in postmenopausal women receiving hormone therapy for breast cancer may help improve quality of life and the ability to plan treatment for cancer. PURPOSE: This phase III trial is studying cognitive function in postmenopausal women with breast cancer receiving hormone therapy on clinical trial IBCSG-1-98.

Detailed description

OBJECTIVES: Primary * Compare cognitive function in postmenopausal women with breast cancer who have received 5 years of adjuvant tamoxifen vs letrozole on protocol IBCSG-1-98. Secondary * Compare cognitive function in patients who have received a single hormonal therapy for 5 years vs those who have received that same hormonal therapy for 3 years, having previously received an alternate hormonal therapy for 2 years. * Compare improvement in cognitive function 1 year after cessation of adjuvant hormonal therapy. * Compare changes in cognitive function in patients who have received prior adjuvant chemotherapy vs those who have not received adjuvant chemotherapy. * Assess the relationship between objective and subjective measures of cognitive function, including specific cognitive domains. * Assess the relationship between cognitive function and psychological distress, fatigue, and quality of life. OUTLINE: This is a longitudinal, multicenter study. Patients undergo cognitive function testing and complete self-reported questionnaires regarding cognitive ability, quality of life, fatigue, and psychosocial status during the fifth year of adjuvant hormonal therapy on protocol IBCSG-1-98 and then during the sixth year\* (post randomization on protocol IBCSG-1-98) (i.e., after completion of adjuvant hormonal therapy). NOTE: \*Patients who receive extended letrozole, hormone replacement therapy, or other endocrine therapy beyond 5 years do not undergo the 6-year assessment. PROJECTED ACCRUAL: A total of 148 patients will be accrued for this study.

Conditions

Interventions

TypeNameDescription
PROCEDUREcognitive assessmentCognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
PROCEDUREfatigue assessment and managementFatigue will be evaluated using the Brief Fatigue Inventory.
PROCEDUREpsychologic distressPsychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
PROCEDUREquality-of-life assessmentQuality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.

Timeline

Start date
2005-04-01
Primary completion
2008-05-01
Completion
2009-05-01
First posted
2006-06-23
Last updated
2012-07-27

Locations

12 sites across 6 countries: Australia, Belgium, Italy, New Zealand, Switzerland, United Kingdom

Source: ClinicalTrials.gov record NCT00343616. Inclusion in this directory is not an endorsement.